ACADIA Pharmaceuticals Inc. vs Phillips 66 — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.45 (market cap $5.06B), while Phillips 66 trades at $224.36 (market cap $86.00B). The key difference: Phillips 66 is far larger — about 17× ACADIA Pharmaceuticals Inc.'s market cap, and Phillips 66 pays a 2.36% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | PSX | |
|---|---|---|
Market Cap | $5.06B | $86.00B |
Sector | Health | Energy |
52-Week High | $29.41 | $224.36 |
52-Week Low | $20.06 | $120.04 |
Enterprise Value | $4.18B | $102.46B |
Dividend Yield | — | 2.36% |
Trailing returns across standard periods
Latest headlines on both assets
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →Phillips 66 is an independent refiner with 12 refineries that have a total crude throughput capacity of 2.0 million barrels per day, or mmb/d, after converting its 255 mb/d Alliance refinery to a terminal. The midstream segment comprises extensive transportation and NGL processing assets. It also includes its DCP Midstream joint venture, which holds 45 natural gas processing facilities, 11 NGL fractionation plants, and a natural gas pipeline system with 58,000 miles of pipeline. Its CPChem chemical joint venture operates facilities in the United States and the Middle East and primarily produces olefins and polyolefins.
Read more on PSX →